RUA Life Sciences (FRA:AOHA) Cash-to-Debt : 10.10 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is RUA Life Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. RUA Life Sciences's cash to debt ratio for the quarter that ended in Mar. 2024 was 10.10.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, RUA Life Sciences could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for RUA Life Sciences's Cash-to-Debt or its related term are showing as below:

FRA:AOHA' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.12 Med: No Debt Max: No Debt
Current: 10.11

During the past 13 years, RUA Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 3.12. And the median was No Debt.

FRA:AOHA's Cash-to-Debt is ranked better than
73.58% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: 1.8 vs FRA:AOHA: 10.11

RUA Life Sciences Cash-to-Debt Historical Data

The historical data trend for RUA Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

RUA Life Sciences Cash-to-Debt Chart

RUA Life Sciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

15.37

8.63

3.12

10.10

RUA Life Sciences Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															8.63	5.53	3.12	1.11	10.10

Competitive Comparison of RUA Life Sciences's Cash-to-Debt

For the Medical Devices subindustry, RUA Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RUA Life Sciences's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where RUA Life Sciences's Cash-to-Debt falls into.

RUA Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

RUA Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.595	/	(0.137	+	0.318)
	=	10.10

RUA Life Sciences's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.595	/	(0.137	+	0.318)
	=	10.10

RUA Life Sciences (FRA:AOHA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

RUA Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of RUA Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

RUA Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RUA Life Sciences PLC (FRA:AOHA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

RUA:UK

Address

2 Drummond Crescent, Ayrshire, Scotland, Irvine, GBR, KA11 5AN

Website

https://www.rualifesciences.com

RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives the majority of its revenue from the USA and has a presence in Switzerland, Italy, the UK, and Israel.

RUA Life Sciences Headlines

No Headlines